MBX Biosciences, Inc. (MBX)

MBX Biosciences was listed on the NASDAQ on September 13, 2024, at $16.00. As of November 27, 2025, the stock was trading at $33.82, with a 52-week range of $4.81 to $34.17. On November 3, 2025, the stock price was $20.61. The latest quarterly earnings per share was -$0.63, with a past EPS surprise of $0.05. The stock has shown significant fluctuation, with a maximum drawdown of 77.71% occurring on April 8, 2025.

As a clinical-stage biopharmaceutical company, the demand for MBX Biosciences' products is not subject to traditional consumer demand seasonality. Its progress and value are primarily driven by clinical trial milestones, regulatory approvals, and the unmet medical needs its therapies address. The company is advancing a pipeline of candidates for endocrine and metabolic disorders with clinically validated targets and established endpoints for regulatory approval.

MBX Biosciences is a clinical-stage biopharmaceutical company focused on developing precision peptide therapies for endocrine and metabolic disorders. It operates within the Pharmaceuticals & Biotech sector, utilizing its PEP platform to design innovative peptide hormone analogs. The company's pipeline includes MBX 2109 (Canvuparatide) in Phase 2 for hypoparathyroidism, MBX 1416 (Imapextide) in Phase 2 for post-bariatric hypoglycemia, and MBX 4291 in IND-enabling studies for obesity.

MBX Biosciences is headquartered in Carmel, Indiana, United States, with its principal executive offices located at 11711 North Meridian Street, Suite 300, Carmel, IN 46032. The company's operations appear to be primarily based in the United States.

MBX Biosciences is focused on addressing unmet medical needs in endocrine and metabolic disorders. It is covered by 10 analysts, with 8 recommending a buy, resulting in a "Strong Buy" rating and a +90.50% upside potential. The company scored higher than 63% of companies evaluated by MarketBeat and has raised $216M in funding. No negative events impacting its brand reputation were found.

MBX Biosciences is a publicly held company. Ownership information is reported via SEC Form 4 and SEC Form 13D, which typically detail top shareholders and insider trading.